Female Pediatric, Adolescent, and Young Adult Oncofertility: A Crucial but Neglected Aspect of Cancer Treatment

authors:

avatar Minoo Taheri 1 , *

MOM Fertility and Infertility Research and Innovation Center, Tehran, Iran
Fertility, Gynecology and Andrology: Vol.2, issue 1; e128702
published online: August 17, 2022
article type: Editorial
received: June 12, 2022
revised: July 11, 2022
accepted: July 16, 2022
DOI: https://doi.org/10.5812/fga-128702

how to cite: Taheri M. Female Pediatric, Adolescent, and Young Adult Oncofertility: A Crucial but Neglected Aspect of Cancer Treatment. Fertil Gynecol Androl. 2022;2(1):e128702. https://doi.org/10.5812/fga-128702.

Globally, more than 8.8 million women are diagnosed with cancer each year. About one-tenth of them are under the age of 40, which includes adolescent young women (ages 15 to 39 years) and pediatric girls (> 14 years) (1, 2). In recent decades, pediatric, adolescent, and young adult (PAYA) cancer outcomes have improved dramatically; 5-year survival rates now exceed 80%. As the number of cancer survivors increases, the rate of survived PAYAs who enter adulthood suffering from late cancer treatment complications will increase.

There are increasingly detailed data documenting that cancer treatments, including radiotherapy and chemotherapy, can lead to diminished ovarian reserve (DOR), infertility, and premature menopause, negatively affecting the survivors’ quality of life (3). Definite cancer (and cancer treatment)-related infertility rates cannot be calculated because there are no definitive criteria to indicate that the patient had been fertile prior to undergoing the cancer treatments or it developed post-treatment. However, it is reported that women of reproductive age who undergo chemotherapy or radiation have a 40 - 80% chance of losing fertility (4). The effects of radiotherapy depend on the dose, site, duration of exposure, and frequency of treatments; the effects of chemotherapy are related to the type and cumulative dose of received chemotherapy.

In addition to radiation and/or chemotherapy in the case of gynecological cancers, patients may require partial or total surgical removal of reproductive organs, which also has obvious implications for fertility. Besides, cancer and its treatment can cause physical and emotional changes, including depression, anxiety, and sexual dysfunction; thus, the loss of fertility can be even more stressful for young women than cancer itself. For this reason, it is of paramount importance to pursue the best cancer treatments available and discuss available strategies to preserve fertility in these vulnerable patients (5).

In 2006 - 2007, the “FertiPROTEKT network” and “Oncofertility consortium” were established to advance reproductive research and fertility preservation (FP) care for cancer survivors (6, 7). Later, in 2009, the “International Society for Fertility Preservation (ISFP)” was established as a pioneering academic society focusing on the importance of FP for cancer patients. Then, an increasing number of fertility preservation societies and networks were also formed in South Korea, Japan, India, Australia, and other countries. The net goal of all these efforts is to open up the new field of reproductive medicine and promote the advancement of FP in cancer patients.

The aim of FP technologies is to help cancer patients to preserve or protect their reproductive potential prior to exposure to treatments. Currently established and experimental options for FP include oocyte and embryo cryopreservation before gonadotoxic treatment, ovarian tissue freezing and autotransplantation, in vitro maturation (IVM), and ovarian protection techniques (8).

Cryopreservation refers to the cooling and storage of viable cells and tissues at ultra-low temperature, at which all biological function is slowed down or completely halted; thus, they can be preserved for future use (9). Embryo and mature oocyte cryopreservation requires at least one cycle of ovarian stimulation and oocyte retrieval. Therefore, while they have been shown to be a feasible, reproducible, safe, and effective approach, they are associated with important risks due to ovarian stimulation. The major limitations of these methods include delayed initiation of cancer treatment if ovarian hyperstimulation syndrome (OHSS) is developed and increased estrogen levels in estrogen-sensitive malignancies (10).

These two main methods of FP can be offered to post-pubertal patients with the desire to have their biological children in the future. However, these cryopreservation methods cannot be offered routinely to pre-pubertal girls due to the inactive hypothalamic-pituitary-ovarian (HPO) axis. In these patients, in addition to risks associated with ovarian stimulation, another concern is that the process of ovarian stimulation and oocyte retrieval requires transvaginal ultrasound scans that necessitate a certain level of physical and psychological maturity. Centered on these biological properties, the most suitable FP options for pre-pubertal girls include ovarian tissue cryopreservation (OTC) for future autotransplantation, IVM, and ovarian protection techniques (11).

OTC involves laparoscopic removal of all or part of the healthy ovarian tissue containing eggs, followed by cryopreservation of the tissue for autotransplantation in the future (12). The tissue graft can be placed orthotopically in the patient’s pelvic cavity (remaining ovary, ovarian fossa, or broad ligament) or can be heterotopically transplanted outside the pelvic cavity (forearm or rectus muscle).

The major advantage of OTC is that ovarian stimulation is not required, avoiding its potential complications, such as OHSS and delay in cancer development. Additionally, OTC does not require sexual maturity, making it a suitable option for pre-pubertal girls. While OTC is still considered investigational at some institutions, it fulfills the criteria for an "established method" (13). In December 2019, the Practice Committee of the American Society of Reproductive Medicine stated that OTC should no more be considered experimental/investigational, and it is an acceptable technique to be offered to patients seeking FP (14, 15).

However, autotransplantation of ovarian tissue from patients with particular types of cancers is associated with the risk of recurrent malignant disease due to the reintroduction of cancer cells (16). Besides, avascular grafting is associated with an increased risk of post-grafting ischemia and follicle atresia. On the other hand, in orthotopic transplantation, pregnancy can occur due to ovulation from the remaining ovary instead of grafted ovarian tissue (17).

IVM of oocytes is another method that does not require ovarian stimulation; however, it is still commonly considered an experimental approach. IVM was first offered to women with polycystic ovary syndrome (PCOS) or poor ovarian reserve who were at OHSS risk following gonadotropin stimulation (18). IVM approach involves the collection of immature oocytes from ovarian antral follicles with minimal or no stimulation, followed by their subsequent maturation in vitro. IVM can be done at the time of oocyte retrieval, or immature oocytes may be immediately cryopreserved for maturation at later stages. However, the number of reported live births after IVM oocyte cryopreservation is very limited.

Given the importance of FP decision-making for cancer potions, especially in PAYA, several guidelines and clinical recommendations have been developed in this context. However, recent studies have reported that most PAYA with cancer and their families did not receive acceptable and satisfying consultation from their healthcare professionals. In particular, they were not always informed about the impact of treatments on their future fertility, available options to preserve their chance to have their child in the future, and alternative family planning (19-21).

Some of the reasons that oncology (or pediatric oncology) clinicians and other medical teams are not willing to have these discussions include, but are not limited to, a lack of knowledge, limited financial resources, concerns about delaying treatment, poor prognosis, and incapability of patients/their family to handle that conversation on top of the many other issues they are emotionally processing (22, 23).

The practice of FP requires a multidisciplinary collaboration between oncologists, fertility specialists, and other involved medical teams prior to the initiation of cancer treatments. Clear information about fertility risks associated with cancer/treatments, adequacy of fertility-sparing approaches, evaluation of reproductive potential, and setting realistic expectations regarding future pregnancy should be provided to all pubertal or post-pubertal patients at the time of diagnosis, whether or not they decide to undergo FP (24, 25). Undoubtedly, FP is associated with unique clinical and ethical challenges regarding consent and beneficence for young cancer patients. FP is time-sensitive as it is better to be done prior to the administration of chemotherapy or radiotherapy. Discussions often take place just days after diagnosis of cancer, with treatment planned to start immediately. During this period, the patient experiences a high level of anxiety and distress. However, many patients claim that the concern about cancer-related infertility is an even more poignant situation than the cancer diagnosis or treatment itself. Besides, reports have demonstrated that the majority of survivors desire to have their own biologic children after therapy, with one primary study reporting that 76% of survivors desire future children (26). In such vulnerable situations, healthcare providers play a crucial role in aiding patients and their families in making a shared decision about FP. Therefore, it is of paramount importance that clinician(s) provide clear and easy-to-understand information about cancer-related infertility, options for FP, costs, and logistics to patients and their families shortly after diagnosis.

References

  • 1.

    Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7-33. [PubMed ID: 33433946]. https://doi.org/10.3322/caac.21654.

  • 2.

    Global cancer statistics for the most common cancers in the world. World Health Organization, International Agency for Research on Cancer; 2022. Available from: https://www.wcrf.org/cancer-trends/worldwide-cancer-data.

  • 3.

    Hao X, Anastacio A, Liu K, Rodriguez-Wallberg KA. Ovarian Follicle Depletion Induced by Chemotherapy and the Investigational Stages of Potential Fertility-Protective Treatments-A Review. Int J Mol Sci. 2019;20(19). [PubMed ID: 31548505]. [PubMed Central ID: PMC6801789]. https://doi.org/10.3390/ijms20194720.

  • 4.

    Mahajan N. Fertility preservation in female cancer patients: An overview. J Hum Reprod Sci. 2015;8(1):3-13. [PubMed ID: 25838742]. [PubMed Central ID: PMC4381379]. https://doi.org/10.4103/0974-1208.153119.

  • 5.

    Pampanini V, Hassan J, Oliver E, Stukenborg JB, Damdimopoulou P, Jahnukainen K. Fertility Preservation for Prepubertal Patients at Risk of Infertility: Present Status and Future Perspectives. Horm Res Paediatr. 2020;93(11-12):599-608. [PubMed ID: 33887724]. https://doi.org/10.1159/000516087.

  • 6.

    Woodruff TK. The Oncofertility Consortium--addressing fertility in young people with cancer. Nat Rev Clin Oncol. 2010;7(8):466-75. [PubMed ID: 20498666]. [PubMed Central ID: PMC3124936]. https://doi.org/10.1038/nrclinonc.2010.81.

  • 7.

    von Wolff M, Andersen CY, Woodruff TK, Nawroth F. FertiPROTEKT, Oncofertility Consortium and the Danish Fertility-Preservation Networks - What Can We Learn From Their Experiences? Clin Med Insights Reprod Health. 2019;13:1179558119845860. [PubMed ID: 31068758]. [PubMed Central ID: PMC6495450]. https://doi.org/10.1177/1179558119845865.

  • 8.

    Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor HS, et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018;36(19):1994-2001. [PubMed ID: 29620997]. https://doi.org/10.1200/JCO.2018.78.1914.

  • 9.

    Iussig B, Maggiulli R, Fabozzi G, Bertelle S, Vaiarelli A, Cimadomo D, et al. A brief history of oocyte cryopreservation: Arguments and facts. Acta Obstet Gynecol Scand. 2019;98(5):550-8. [PubMed ID: 30739329]. https://doi.org/10.1111/aogs.13569.

  • 10.

    Ozcan MC, Snegovskikh V, Adamson GD. Oocyte and embryo cryopreservation before gonadotoxic treatments: Principles of safe ovarian stimulation, a systematic review. Womens Health (Lond). 2022;18. [PubMed ID: 35130799]. [PubMed Central ID: PMC8829712]. https://doi.org/10.1177/17455065221074886.

  • 11.

    Ben-Aharon I, Abir R, Perl G, Stein J, Gilad G, Toledano H, et al. Optimizing the process of fertility preservation in pediatric female cancer patients - a multidisciplinary program. BMC Cancer. 2016;16:620. [PubMed ID: 27506811]. [PubMed Central ID: PMC4979150]. https://doi.org/10.1186/s12885-016-2584-7.

  • 12.

    Silber SJ, Goldsmith S, Castleman L, Hurlbut K, Fan Y, Melnick J, et al. In-vitro maturation and transplantation of cryopreserved ovary tissue: understanding ovarian longevity. Reprod Biomed Online. 2022;44(3):504-14. [PubMed ID: 35151573]. https://doi.org/10.1016/j.rbmo.2021.11.015.

  • 13.

    Donnez J, Dolmans MM. Fertility Preservation in Women. N Engl J Med. 2017;377(17):1657-65. [PubMed ID: 29069558]. https://doi.org/10.1056/NEJMra1614676.

  • 14.

    Diaz-Garcia C, Domingo J, Garcia-Velasco JA, Herraiz S, Mirabet V, Iniesta I, et al. Oocyte vitrification versus ovarian cortex transplantation in fertility preservation for adult women undergoing gonadotoxic treatments: a prospective cohort study. Fertil Steril. 2018;109(3):478-485 e2. [PubMed ID: 29428307]. https://doi.org/10.1016/j.fertnstert.2017.11.018.

  • 15.

    Practice Committee of the American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril. 2019;112(6):1022-33. [PubMed ID: 31843073]. https://doi.org/10.1016/j.fertnstert.2019.09.013.

  • 16.

    Peek R, Bastings L, Westphal JR, Massuger LF, Braat DD, Beerendonk CC. A preliminary study on a new model system to evaluate tumour-detection and tumour-purging protocols in ovarian cortex tissue intended for fertility preservation. Hum Reprod. 2015;30(4):870-6. [PubMed ID: 25662807]. https://doi.org/10.1093/humrep/dev013.

  • 17.

    Salama M, Woodruff TK. New advances in ovarian autotransplantation to restore fertility in cancer patients. Cancer Metastasis Rev. 2015;34(4):807-22. [PubMed ID: 26589603]. [PubMed Central ID: PMC4722873]. https://doi.org/10.1007/s10555-015-9600-2.

  • 18.

    Son WY, Henderson S, Cohen Y, Dahan M, Buckett W. Immature Oocyte for Fertility Preservation. Front Endocrinol (Lausanne). 2019;10:464. [PubMed ID: 31379739]. [PubMed Central ID: PMC6650526]. https://doi.org/10.3389/fendo.2019.00464.

  • 19.

    Benedict C, Thom B, N. Friedman D, Diotallevi D, M. Pottenger E, J. Raghunathan N, et al. Young adult female cancer survivors' unmet information needs and reproductive concerns contribute to decisional conflict regarding posttreatment fertility preservation. Cancer. 2016;122(13):2101-9. [PubMed ID: 27213483]. [PubMed Central ID: PMC4911318]. https://doi.org/10.1002/cncr.29917.

  • 20.

    Yeomanson DJ, Morgan S, Pacey AA. Discussing fertility preservation at the time of cancer diagnosis: dissatisfaction of young females. Pediatr Blood Cancer. 2013;60(12):1996-2000. [PubMed ID: 23836521]. https://doi.org/10.1002/pbc.24672.

  • 21.

    Mulder RL, Font-Gonzalez A, Hudson MM, van Santen HM, Loeffen EAH, Burns KC, et al. Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2021;22(2):e45-56. [PubMed ID: 33539753]. https://doi.org/10.1016/S1470-2045(20)30594-5.

  • 22.

    Gupta AA, Edelstein K, Albert-Green A, D'Agostino N. Assessing information and service needs of young adults with cancer at a single institution: the importance of information on cancer diagnosis, fertility preservation, diet, and exercise. Support Care Cancer. 2013;21(9):2477-84. [PubMed ID: 23604520]. https://doi.org/10.1007/s00520-013-1809-4.

  • 23.

    Quinn GP, Vadaparampil ST, Fertility Preservation Research G. Fertility preservation and adolescent/young adult cancer patients: physician communication challenges. J Adolesc Health. 2009;44(4):394-400. [PubMed ID: 19306799]. https://doi.org/10.1016/j.jadohealth.2008.08.014.

  • 24.

    Lambertini M, Del Mastro L, Pescio MC, Andersen CY, Azim HJ, Peccatori FA, et al. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med. 2016;14:1. [PubMed ID: 26728489]. [PubMed Central ID: PMC4700580]. https://doi.org/10.1186/s12916-015-0545-7.

  • 25.

    Peccatori FA, Azim HJ, Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi160-70. [PubMed ID: 23813932]. https://doi.org/10.1093/annonc/mdt199.

  • 26.

    Schover LR, Rybicki LA, Martin BA, Bringelsen KA. Having children after cancer. A pilot survey of survivors' attitudes and experiences. Cancer. 1999;86(4):697-709. [PubMed ID: 10440699]. https://doi.org/10.1002/(sici)1097-0142(19990815)86:4<697::aid-cncr20>3.0.co;2-j.